Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
